273 related articles for article (PubMed ID: 30049194)
21. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract][Full Text] [Related]
22. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
23. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
24. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
25. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
26. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
[TBL] [Abstract][Full Text] [Related]
27. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
[TBL] [Abstract][Full Text] [Related]
28. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].
He F; Li T; Li YF; Tang P; Sang LN; Huang YM; Sun L; Liu L
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):681-687. PubMed ID: 37263951
[No Abstract] [Full Text] [Related]
30. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
Patnaik MM; Lasho TL; Hodnefield JM; Knudson RA; Ketterling RP; Garcia-Manero G; Steensma DP; Pardanani A; Hanson CA; Tefferi A
Blood; 2012 Jan; 119(2):569-72. PubMed ID: 22096241
[TBL] [Abstract][Full Text] [Related]
31. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
32. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
34. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
[TBL] [Abstract][Full Text] [Related]
35. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
[TBL] [Abstract][Full Text] [Related]
36. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
37. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
Duetz C; Westers TM; In 't Hout FEM; Cremers EMP; Alhan C; Venniker-Punt B; Visser-Wisselaar HA; Chitu DA; de Graaf AO; Smit L; Jansen JH; van de Loosdrecht AA
Br J Haematol; 2021 May; 193(4):798-803. PubMed ID: 33765355
[TBL] [Abstract][Full Text] [Related]
38. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
39. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
40. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]